However, pediatric clinical trials have shown limited long-term single-agent ALK-TKI activity for neuroblastoma, because innate or acquired resistance often leads to drug inefficacy and tumor recurrence (14, 17, 20, 22, 57). This evidence concerns the gene ALK and neuroblastoma.